MDACC Study No:2011-0382 ( NCT No: NCT01363817)
Title:Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-906024 in Subjects with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Principal Investigator:Patrick Zweidler-McKay
Treatment Agent:BMS-906024
Study Status:Closed
Study Description:(AU: The above line has been added to 1. "If you are reading and signing this
form on behalf of a potential participant, please note: Any time the words
"you," "your," "I," or "me" appear, it is meant to apply to the potential
The goal of this clinical research study is to find the highest tolerable dose
of BMS-906024 that can be given to patients with relapsed or refractory T cell
leukemia or lymphoma. The safety of this drug will also be studied.

BMS-906024 is designed to block an enzyme called gamma secretase. This enzyme
is important in most T cell leukemias and lymphomas. Blocking this enzyme may
help to control the disease. This is the first study using BMS-906024 in
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase I
Treatment Agents:BMS-906024
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol-Myers Squibb
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Patrick Zweidler-McKay
For Clinical Trial Enrollment:713-745-4616
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults